Jim Beiermann and Danny Irland, both of Southwestern Health Resources, discuss their focus of value-based care through ACO and Next Generation Programs.
Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.
Approximately two-thirds of Employers Health clients now exclude GLP-1s for obesity, up from a roughly even split at launch as cost drives coverage decisions.
Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.
A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.